What is important for people with nontuberculous mycobacterial disease? An EMBARC-ELF patient survey

• Michal Shteinberg,
• Jeanette Boyd,
• Stefano Aliberti,
• Eva Polverino,
• Bridget Harris,
• Tove Berg,
• Annette Posthumus,
• Thomas Ruddy,
• Pieter Goeminne,
• Ernie Lloyd,
• Timothy Alan,
• Josje Altenburg,
• Barbara Crossley,
• Francesco Blasi,
• James Chalmers

Affiliations

Michal Shteinberg

Pulmonology Institute and CF Center, Carmel Medical Center and the Technion, Israel Institute of Technology, Haifa, Israel

Jeanette Boyd

European Lung Foundation, Sheffield, UK

Stefano Aliberti

Dept of Pathophysiology and Transplantation, University of Milan, and Internal Medicine Dept, Respiratory Unit and Cystic Fibrosis Adult Center, Milan, Italy

Eva Polverino

Pneumology Dept, Hospital Universitari Vall d'Hebron, Barcelona, Spain

Bridget Harris

European Lung Foundation Bronchiectasis Patient Advisory Group, Edinburgh, UK

Tove Berg

European Lung Foundation Bronchiectasis Patient Advisory Group, Edinburgh, UK

Annette Posthumus

European Lung Foundation Bronchiectasis Patient Advisory Group, Edinburgh, UK

Thomas Ruddy

European Lung Foundation Bronchiectasis Patient Advisory Group, Edinburgh, UK

Pieter Goeminne

Dept of Respiratory Medicine, AZ Nikolaas, Sint-Niklaas, Belgium

Ernie Lloyd

European Lung Foundation Bronchiectasis Patient Advisory Group, Edinburgh, UK

Timothy Alan

European Lung Foundation Bronchiectasis Patient Advisory Group, Edinburgh, UK

Josje Altenburg

Dept of Respiratory Medicine, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands

Barbara Crossley

European Lung Foundation Bronchiectasis Patient Advisory Group, Edinburgh, UK

Francesco Blasi

Dept of Pathophysiology and Transplantation, University of Milan, and Internal Medicine Dept, Respiratory Unit and Cystic Fibrosis Adult Center, Milan, Italy

James Chalmers

Scottish Centre for Respiratory Research, University of Dundee, Ninewells Hospital and Medical School, Dundee, UK